Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe
Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML).
Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed.
VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherapy following consolidation, based on the results from the QuANTUM-First trial.
“This agreement with GENESIS Pharma represents an important step in our ambition to expand access to our innovative targeted medicine across Central and Eastern Europe,” said Markus Kosch, MD, Head, Oncology Business Division Europe and Canada, Daiichi Sankyo. “By combining our scientific expertise with the strong regional footprint of GENESIS Pharma, we aim to accelerate access to VANFLYTA for patients with newly-diagnosed FLT3-ITD positive AML and ultimately help improve outcomes in this high-risk population.”
“This new strategic collaboration marks another significant milestone for our company, reinforcing our long-standing expertise and focus on advancing medicines for difficult-to-treat cancers,” said Constantinos Evripides, Managing Director, GENESIS Pharma. “Daiichi Sankyo has entrusted us with a broad territory across Central and Eastern Europe and we look forward to working together to accelerate access to VANFLYTA across the region.”
About FLT3-ITD Positive Acute Myeloid Leukemia
Almost 487,300 new cases of leukemia were reported globally in 2022, with more than 305,400 deaths.1 AML accounts for 23.1% of total leukemia cases worldwide and is most common in adults.2,3 In Europe, approximately 18,000 people are diagnosed with AML each year and the five-year survival rate is reported at 17% for adult patients.4,5 A number of gene mutations have been identified in AML and FLT3 (FMS-like tyrosine kinase 3) mutations are the most common.6 Approximately 80% of FLT3 mutations are FLT3-ITD mutations, which drive cancer growth and contribute to particularly unfavorable prognosis including increased risk of relapse and shorter overall survival.7,8FLT3-ITD mutations occur in about 25-30% of all adult patients suffering from AML.7,8
About VANFLYTA
VANFLYTA is an oral, highly potent and selective type II FLT3 inhibitor approved in more than 30 countries/regions in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherapy following consolidation, for the treatment of adult patients with newly diagnosed AML that is FLT3-ITD positive based on the results from the QuANTUM-First trial. In the U.S., VANFLYTA is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with VANFLYTA in this setting has not been demonstrated.
In Japan, VANFLYTA is also approved for the treatment of patients with relapsed/refractory AML that is FLT3-ITD mutation positive, as detected by an approved test, based on results from the QuANTUM-R trial.
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical need. For more information, please visit www.daiichi-sankyo.eu.
About GENESIS Pharma
GENESIS Pharma is a regional biopharma company focused on the commercialization of innovative biopharmaceutical products targeting severe and rare diseases in Central and Eastern Europe. Established in 1997, GENESIS Pharma was among the first pharmaceutical companies in Europe to specialize in the marketing, sales and distribution of biopharmaceutical products. GENESIS Pharma maintains a strong portfolio in therapeutic areas with high unmet medical need through long standing strategic alliances with some of the leading global biopharma companies. For more information, please visit www.genesispharma.com and follow us on LinkedIn.
References: | |
1 Global Cancer Observatory. Population Fact Sheet: World. Updated February 2024. | |
2 American Cancer Society: Key Statistics for Acute Myeloid Leukemia. Updated January 2023 | |
3 Dong Y, et al. Exp Hematol Oncol. (2020);9:14. | |
4 Rodriguez-Abreu D, et al. Ann Oncol. (2007);18 Suppl 1:i3-i8 | |
5 Heuser M, et al. Ann Oncol. (2020) 31(6):697-712. | |
6 Kennedy VE, et al. Front Onc. 23 December 2020;10. Volume 10 – 2020 | |
7 Daver N, et al. Leukemia. (2019) 33:299-312. | |
8 Patel JP, et al N Engl J Med. (2012) Mar 22;366(12):1079-89. | |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260106502657/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zilch to Acquire Fjord Bank to Kickstart European Expansion8.1.2026 01:40:00 CET | Press release
Acquisition will provide Zilch, the UK and EMEA’s fastest-growing fintech unicorn, with a European banking licence as it eyes international rollout Zilch, the consumer payments platform powering the future of commerce, today announces it has signed an agreement to acquire AB Fjord Bank, a Lithuania-based bank with approx. $120M in total assets that is authorised and regulated by the Bank of Lithuania and the European Central Bank. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107714872/en/ Zilch to Acquire Fjord Bank to Kickstart European Expansion The acquisition will represent a major strategic milestone for Zilch, providing a European banking licence that will enable the accelerated rollout of its offering across Europe. Zilch will purchase 100% of Fjord Bank and will establish Lithuania as its European headquarters as a consequence of the transaction, using Vilnius as its operational and regulatory platform for expan
Novotech Appoints Anand Tharmaratnam as New CEO8.1.2026 01:01:00 CET | Press release
Novotech, a globally recognized full-service biotech clinical research organization (CRO), is pleased to announce the appointment of Dr. Anand Tharmaratnam as its new Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107098568/en/ Dr. Anand Tharmaratnam, Novotech CEO and Chairman Dr. Tharmaratnam brings nearly three decades of experience in the global CRO industry and has served as Novotech Chairman since 2021. He commenced as Chairman and CEO on 1 January 2026. Reflecting Novotech’s increasingly international profile, Dr. Tharmaratnam will be based at the company’s new global headquarters in Singapore. The appointment follows a thoughtful and considered process. In early September 2025, Novotech’s former CEO Dr. John Moller informed employees of his intention to step down from the position at the end of last year, after nine years in the CEO role. The decision followed the successful completion of t
Quectel Launches RG660QA and RG660QB 5G Modules With Advanced Performance Features7.1.2026 18:00:00 CET | Press release
Quectel Wireless Solutions, an end-to-end global IoT solutions provider, today announces the launch of the RG600QA and RG660QB 5G module, based on the Qualcomm® X85 and X82 5G Modem-RF Systems. The RG660QA is based on X85 while the RG660QB is based onX82. Engineering samples of two first SKUs in the RG660Qx series have been already made available to customers and pre-production samples will be available to the market in Q2 2026. Designed for versatility, this module series supports a broad array of next generation 5G use cases, from home and business wireless broadband to mobile video, camera applications, and high-performance mobile hotspots. In indoor 5G CPE, it unlocks premium performance by enabling Wi-Fi 7 across the 2.4 GHz, 5 GHz, and 6 GHz bands, with integrated Bluetooth to support a full ecosystem of connected devices. With Ethernet speeds reaching up to 10 Gbps, the RG660Qx delivers the high-capacity backbone needed to power ultra-fast, reliable home and enterprise networks.
Sodali & Co Announces Executive Leadership Appointments7.1.2026 17:00:00 CET | Press release
Accelerates Firm Strategy to Deliver Global Integrated Stakeholder Solutions Sodali & Co (the ‘firm’ or ‘Sodali’), the leading global capital markets-centric stakeholder advisory firm, is pleased to announce four appointments to its Executive Leadership Team (ELT) under Chief Executive Officer Andrew Benett. These newly created senior roles will strengthen Sodali’s ability to respond to clients’ evolving needs with an integrated suite of shareholder, sustainability, and strategic communications advisory services delivered on a global scale. The appointments are as follows: Brett Clegg has been promoted to Chief Commercial Officer. Brett was previously Chairman of Sodali’s APAC region, based in the firm’s Sydney office. He specializes in advising clients on strategic communications, issues management, and capital markets transactions. Prior to Sodali, Brett spent over two decades in senior executive and editorial roles at some of Australia’s leading news brands, including The Australian
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom